Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Fetal drug exposure after maternally administered CFTR modulators Elexacaftor/Tezacaftor/Ivacaftor in a rat model.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 1 Feb 2024

Li Danni, Zhu Yimin, Donnelley Martin, Parsons David, Habgood Mark D, Schneider-Futschik Elena K

Abstract excerpt

BACKGROUND: The potential effects of the very effective cystic fibrosis triple combination drug, Elexacaftor/Tezacaftor/Ivacaftor (ETI) in pregnancy on prenatal development of offspring remain largely unknown. RESEARCH QUESTION: We aimed to investigate the fetal tissue distribution pattern of maternally administered ETI by placental transfer in the rat fetuses. STUDY DESIGN AND METHODS: Sprague Dawley pregnant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Benzodioxoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Placenta

Share to Pyrazoles

Share to Pyridines

Share to Pyrrolidines

Share to Quinolones

Source

Identifiers

PMID: 38232663
DOI: 10.1016/j.biopha.2024.116155

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Fetal drug exposure after maternally administered CFTR modulators Elexacaftor/Tezacaftor/Ivacaftor in a rat model.PMID 38232663Read ↗

Extent of foetal exposure to maternal elexacaftor/tezacaftor/ivacaftor during pregnancySemantic proximity Read ↗

"Shifting sands in cystic fibrosis": impacts of CFTR modulators on reproductive health in people with cystic fibrosis and challenges related to in utero exposure.Semantic proximity Read ↗

Use of elexacaftor/tezacaftor/ivacaftor combination in pregnancy.Semantic proximity Read ↗

Determinants of drug entry into the developing brainSemantic proximity Read ↗

CFTR modulator therapy via carrier mother to treat meconium ileus in a F508del homozygous fetus: Insights from an unsuccessful caseSemantic proximity Read ↗

Elexacaftor/Tezacaftor/Ivacaftor alters branching morphogenesis of the mouse embryonic lungSemantic proximity Read ↗

Drug Interactions at the Human Placenta: What is the Evidence?Semantic proximity Read ↗

Mechanisms regulating toxicant disposition to the embryo during early pregnancy: An interspecies comparisonSemantic proximity Read ↗

Congenital bilateral cataracts in newborns exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breast feeding.Semantic proximity Read ↗

Digital twin-enhanced three-organ microphysiological system for studying drug pharmacokinetics in pregnant womenSemantic proximity Read ↗

ILSI/HESI maternal toxicity workshop summary: maternal toxicity and its impact on study design and data interpretationSemantic proximity Read ↗

Safety of elexacaftor/tezacaftor/ivacaftor dose reduction: Mechanistic exploration through physiologically based pharmacokinetic modeling and a clinical case series.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.